Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - CANNABIS SCIENCE, INC.Financial_Report.xls
EX-32.1 - EXHIBIIT 32.1 - CANNABIS SCIENCE, INC.exhibit321.htm
EX-31.2 - EXHIBIIT 31.2 - CANNABIS SCIENCE, INC.exhibit312.htm
EX-31.1 - EXHIBIIT 31.1 - CANNABIS SCIENCE, INC.exhibit311.htm
EX-32.2 - EXHIBIIT 32.2 - CANNABIS SCIENCE, INC.exhibit322.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q/A

Amendment No. 1


[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended: June 30, 2011


OR


[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from __________ to ___________


Commission File Number: 001-28911



CANNABIS SCIENCE, INC.

 (Exact name of registrant as specified in its charter)

 

 

 

Nevada

91-1869677

(State or other jurisdiction of incorporation or

(I.R.S. Employer Identification No.)

organization)

 

 

2422 S. Trenton Way, Unit H, Denver, CO 80231

(Address of principal executive offices,

including zip code)


888-889-0888

(Registrant’s telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes (X)   No (  )


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted

and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required

to submit and post such files).  Yes (X)   No (  )


Indicate by check if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  (X)


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a not-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


 

Large accelerated    (  )         Accelerated filer   (  )


Non-accelerated filer  (  )       Smaller reporting company   (X)


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes (  )   No (X)


As of August 12, 2011, the Company had 171,120,574 shares of Common Stock outstanding.

 

                 

              

 

CANNABIS SCIENCE, INC.

FORM 10-Q

For the Period Ended June 30, 2011

 

 

EXPLANATORY NOTE

 

The sole purpose of this Amendment to the Registrant’s Quarterly Report on Form 10-Q for the period ended June 30, 2010 (the “10-Q”), is to furnish the Interactive Data File exhibits required by Item 601(b)(101) of Regulation S-K. No other changes have been made to the 10-Q, and this Amendment has not been updated to reflect events occurring subsequent to the filing of the 10-Q.

 

 

 

TABLE OF CONTENTS

 


 

Page

PART I   FINANCIAL INFORMATION

3

Item 1.

Financial Statements

3

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

4

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

5

Item 4.

Controls and Procedures

5


PART II  OTHER INFORMATION

6

Item 1.

Legal Proceedings

6

Item 1A.

Risk Factors

6

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

6

Item 3.

Defaults Upon Senior Securities

7

Item 4.

Submission of Matters to a Vote of Security Holders

7

Item 5.

Other Information

7

Item 6.

Exhibits and Certifications

7

 

 


2

                 

              






PART 1 FINANCIAL INFORMATION.


ITEM 1.  FINANCIAL STATEMENTS


CANNABIS SCIENCE, INC.

 

 

Page No.

Balance Sheets as at June 30, 2011 and December 31, 2010

F-1

Statements of Operations for the three and six months ended June 30, 2011 and 2010 and for the period January 27, 2005 (Inception) to June 30, 2011

F-2

Statements of Shareholders’ Equity/(Deficit) for the Period from January 27, 2005 (inception) to June 30, 2011

F-3

Statements of Cash Flows for the six months ended June 30, 2011 and 2010 and for the period January 27, 2005 (Inception) to June 30, 2011

F-5

Notes to Financial Statements

F-6

 

3

                 

              



 

 

 

 

 

CANNABIS SCIENCE, INC.

(A Development Stage Company)

Balance Sheets

June 30, 2011 and December 31, 2010

 

 

June 30,

 

 

 

 

2011

 

December 31,

 

 

(unaudited)

$

 

 2010

$

ASSETS 

 

 

 

 

Current Assets 

 

 

 

 

Cash 

 

942

 

 1,190 

Prepaid expenses

 

3,127

 

 18,009   

Total current assets 

 

4,069

 

19,199 

 

 

 

 

 

Deposits

 

6,666

 

6,666

Computer and Equipment, net of accumulated 

 

 

 

 

  depreciation of $3,080 and $2,389

 

1,490

 

2,181 

 

 

 

 

 

Intangibles, net of accumulated amortization

 

 

 

 

  of $67,838 and $57,264

 

58,162

 

68,736 

TOTAL ASSETS 

 

70,387

 

96,782 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT 

 

 

 

 

Current Liabilities 

 

 

 

 

Accounts payable 

 

452,080

  

393,753 

Accrued expenses 

 

1,065,318

 

675,000 

Advances from related parties 

 

154,158

 

107,835 

Advances from officers 

 

-

 

1,807 

Notes payable to stockholders

 

195,855

 

171,509

Deferred license revenue 

 

-

 

73,334 

Total current liabilities and total liabilities 

 

1,867,411

 

1,423,238 

 

 

 

 

 

Stockholders’ Deficit

 

 

 

 

Preferred stock, $0.001 par value 

 

 

 

 

  Authorized 1,000,000 shares 

 

 

 

 

  Issued and outstanding, 999,999 shares 

 

 

 

 

  respectively 

 

1,000 

 

1,000 

Common stock, $0.001 par value 

 

 

 

 

  Authorized 250,000,000 shares 

 

 

 

 

  Issued and outstanding, 157,320,574 shares and 

 

 

 

 

  101,170,574, respectively 

 

157,321

 

101,171 

Prepaid consulting

 

(425,075

)

(1,322,630)

Additional paid-in capital 

 

65,224,103

 

62,091,628 

Accumulated deficit 

 

(66,754,373

)

(62,197,625)

Total stockholders' deficit 

 

(1,797,024

)

(1,326,456)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT 

 

70,387

 

96,782 

  

 

 

  

The accompanying notes are an integral part of these financial statements. 

 

 

 

F-1

                 

              




CANNABIS SCIENCE, INC.

(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF OPERATIONS

FOR THE THREEE AND SIX MONTHS ENDED JUNE 30, 2011 AND 2010

AND THE CUMULATIVE PERIOD FROM JANUARY 27, 2005 (INCEPTION) TO JUNE 30, 2011

(UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

For the six months

ended June 30,

Period from January 27, 2005 (inception) to June 30, 2011

 

 

For the three months

ended June 30,

 

 

2011

 

2010

 

2011

2010 

 

 

 

$

 

$

 

$

$

$

Revenue 

 

62,044

 

-

 

73,334

-

89,739 

 

 

 

 

 

 

 

 

 

Operating Expenses 

 

 

 

 

 

 

 

 

Investor relations

 

15,392

 

10,295

 

15,392

45,795

1,136,184 

Professional fees 

 

33,650

 

810

 

45,030

1,875

32,696,210 

Technology license royalties 

 

-

 

-

 

-

-

160,417 

Impairment of oil and gas well lease 

 

-

 

-

 

-

-

5,089,811 

Net loss (gain) on settlement of liabilities* 

 

884,600

 

1,007,000

 

2,371,700

1,477,000

2,112,237

Depreciation and Amortization 

 

5,827

 

5,557

 

11,264

16,178

70,484 

General and administrative 

 

889,750

 

568,802

 

2,186,359

673,727

21,966,219 

Total operating expenses 

 

1,829,219

 

1,592,464

 

4,629,745

2,214,575

63,231,562 

Net Operating Profit (Loss)

 

(1,767,175)

 

(1,592,464)

 

(4,566,411)

(2,214,575)

(63,141,823)

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

66,021 

Interest expense, net 

 

205

 

-

 

(337)

-

(153,711)

Beneficial conversion feature 

 

-

 

-

 

-

-

(1,098,992)

Net Income (Loss) Before Income Taxes 

 

(1,766,970)

 

(1,592,464)

 

(4,556,748)

(2,214,575)

(64,328,505)

Income tax provision 

 

-

 

-

 

-

-

(2,035,065)

Income tax benefit 

 

-

 

-

 

-

-

1,210,270 

Net tax 

 

-

 

-

 

-

-

(824,795)

 

 

 

 

 

 

 

 

 

Net Income (Loss) From Continuing 

 

 

 

 

 

 

 

 

Operations 

 

(1,766,970)

 

(1,592,464)

 

(4,556,748)

(2,214,575)

(65,153,300)

Discontinued operations 

 

-

 

-

 

-

-

(2,425,868)

Income tax benefit 

 

-

 

-

 

-

-

824,795 

Net Loss 

 

(1,766,970)

 

(1,592,464)

 

(4,556,748)

(2,214,575)

(66,754,373)

 

 

 

 

 

 

 

 

 

Net loss per common share 

 

 

 

 

 

 

 

 

- Basic and diluted 

 

$        0.01

 

$         0.04

 

$        0.04

$       0.06

 

 

 

 

 

 

 

 

 

 

Weighted average number of 

 

 

 

 

 

 

 

 

common shares outstanding 

 

139,219,475

 

37,824,821

 

126,364,220

35,265,888

 

 

 

 

 

The accompanying notes are an integral part of these financial statements.


F-2

                 

              


 




CANNABIS SCIENCE, INC.

(A DEVELOPMENT STAGE COMPANY)

STATEMENT OF SHAREHOLDERS’ EQUITY/(DEFICIT)

FOR THE PERIOD FROM JANUARY 27, 2005 (inception) to JUNE 30, 2011

(Unaudited)

 

 

 

 

 

Additional

 

 

 

 

Preferred

Common

Paid-in

Prepaid

Accum.

 

 

Shares

Par

Shares

Par

Capital

Consulting

Deficit

Total

 

 

$

 

$

$

$

$

$

Bal, Jan 27, 2005 

 -

-

 

Founder's stock issued 

 

 

83,800 

84 

(84)

 

 

Stock issued for debt 

 

 

8,000 

399,992 

 

 

400,000 

Shares issued for 

 

 

 

 

 

 

 

 

license agreement 

 

 

86,188 

86 

(86)

 

 

Effect of reverse merger 

 

 

13,840 

14 

(200,014)

 

 

(200,000)

Divestiture of subsidiary 

 

 

 

 

 

 

 

 

to related party 

 

 

544,340 

 

 

544,340 

Net loss for the period 

 

 

 

 

 

 

(807,600)

(807,600)

Bal, Dec 31, 2005 

191,828 

192 

744,148 

(807,600)

(63,260)

Shares issued for 

 

 

 

 

 

 

 

 

employment 

 

 

45,500 

45 

8,487,455 

 

 

8,487,500 

Shares issued for 

 

 

 

 

 

 

 

 

service 

 

 

171,080 

171 

28,798,329 

(7,633,750)

 

21,164,750 

Shares issued for 

 

 

 

 

 

 

 

 

lease agreement 

 

 

6,770 

406,193 

 

(350,200)

56,000 

Net loss for the year 

 

 

 

 

 

 

(36,906,584)

(36,906,584)

Bal, Dec 31, 2006 

415,178 

415 

38,436,125 

(7,633,750)

(38,064,384)

(7,261,594)

Shares issued for 

 

 

 

 

 

 

 

 

service 

 

 

63,020 

63 

528,285 

(387,500)

 

140,848 

Shares issued for 

 

 

 

 

 

 

 

 

debt 

 

 

350,000 

350 

349,650 

 

 

350,000 

Amortization of 

 

 

 

 

 

 

 

 

beneficial conversion 

 

 

 

 

 

 

 

 

feature 

 

 

 

 

1,066,657 

 

 

1,066,657 

Amortization of shares 

 

 

 

 

 

 

 

 

issued for services 

 

 

 

 

 

8,021,250

 

8,021,250 

Shares issued for 

 

 

 

 

 

 

 

 

properties 

 

 

500,000 

500 

4,999,500 

 

 

5,000,000 

Net loss for the year 

 

 

 

 

 

 

(15,007,117)

(15,007,117)

Bal, Dec 31, 2007 

1,328,198 

1,328 

45,380,217 

(53,071,501)

(7,689,956)

 

 

  

The accompanying notes are an integral part of these financial statements.

 

 

 

F-3

                 

              


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

Preferred

Common

Paid-in

Prepaid

Accum.

 

 

Shares

Par

Shares

Par

Capital

Consulting

Deficit

Total

 

 

$

 

$

$

$

$

$

Bal, Dec 31, 2007 

 -

1,328,198 

1,328 

45,380,217 

(53,071,501)

(7,689,956)

Amortization of 

 

 

 

 

 

 

 

 

beneficial conversion 

 

 

 

 

 

 

 

 

feature 

 

 

 

 

32,335 

 

 

32,335 

Cancellation and 

 

 

 

 

 

 

 

 

amortization of shares 

 

 

(919)

(1)

 

 

Shares issued for cash 

 

 

10,000 

10 

19,990 

 

 

20,000 

Shares issued for debt 

 

 

990,000 

990 

98,010 

 

 

99,000 

Shares issued for 

 

 

 

 

 

 

 

 

acquisition 

 

 

10,000,000 

10,000 

2,490,000 

 

 

2,500,000 

Shares issued for 

 

 

 

 

 

 

 

 

service 

 

 

270,000 

270 

128,230 

 

 

128,500 

Net profit for the year 

 

 

 

 

 

 

3,559,617 

3,559,617 

Bal, Dec 31, 2008 

12,597,279 

12,597 

48,148,783 

(49,511,884)

(1,350,504)

Shares issued for cash 

 

 

2,522,495 

2,523 

197,552 

 

 

200,075 

Shares issued for 

 

 

 

 

 

 

 

 

service 

 

 

8,855,000 

8,855 

2,507,195 

 

 

2,516,050 

Cancellation of shares 

 

 

(10,000)

(10)

10 

 

 

Shares issued for debt 

 

 

3,680,000 

3,680 

2,020,320 

 

 

2,024,000 

Shares issued for 

 

 

 

 

 

 

 

 

service 

999,999 

1,000 

 

 

 

 

 

1,000 

Shares issued for 

 

 

 

 

 

 

 

 

assets 

 

 

2,100,000 

2,100 

123,900 

 

 

126,000 

Net loss for the year 

 

 

 

 

 

 

(4,532,061)

(4,532,061)

Bal, Dec 31, 2009 

999,999 

1,000 

29,744,774 

29,745 

52,997,760 

(54,043,945)

(1,015,440)

Common stock issued for cash

-

-

1,245,800 

1,246 

137,540 

 

-

138,786 

Common stock issued for services

-

-

26,680,000 

26,680 

3,670,978 

( 3,530,808)

-

166,850 

Common stock issued for acquisition write-off

-

-

350,000

350

36,150

-

-

36,500

Common stock issued for debt 

-

-

42,750,000 

42,750

5,249,600

-

-

5,292,350 

Amortization of shares issued for services

-

-

-

-

-

2,208,178

-

   

2,208,178

Common shares pending cancelation

-

-

400,000 

400 

(400) 

 

-

Net loss for the period 

-

-

 -

 -

 -

 -

(8,153,680)

(8,153,680)

Bal, Dec 31, 2010

999,999 

1,000 

101,170,574 

101,171

62,091,628

(1,322,630)

(62,197,625)

(1,326,456)

Common stock issued for services

-

-

17,250,000

17,250

760,375

(749,900)

-

27,725

Common stock issued for debt 

-

-

39,300,000 

39,300

2,371,700

 -

-

2,411,000 

Amortization of shares issued for services

-

-

-

-

-

1,647,455

-

   

1,647,455

Common shares canceled

-

-

(400,000)

(400)

400

-

-

-

Net loss for the period 

-

-

 -

 -

 -

 -

(4,556,748)

(4,556,748)

Bal, June 30, 2011

999,999 

1,000 

157,320,574 

157,321

65,224,103

(425,075)

(66,754,373)

(1,797,024)

 

 

The accompanying notes are an integral part of these financial statements.

 

 

 

F-4

                 

              

 

 

 

 

 

 

 

 

CANNABIS SCIENCE, INC.

(A Development Stage Company)

STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

 

 

 

Period from

 

 

 

 

 

 

January 27,

 

 

 

 

 

 

2005

 

 

For the six months

 

(inception) to

 

 

ended June 30,

 

June 30,

 

 

2011

 

2010

 

2011

 

 

$

 

$

 

$

CASH FLOWS FROM OPERATING ACTIVITIES: 

 

 

 

 

 

 

Net loss 

 

(4,556,748)

(2,214,575)

 

(66,754,373)

Plus: 

 

 

 

 

 

 

Income from discontinued operations 

 

-

 

-

 

1,601,073

Total net loss 

 

(4,556,748)

 

(2,214,575)

 

(65,153,300)

Adjustments to reconcile net loss to net 

 

 

 

 

 

 

cash used in operating activities: 

 

 

 

 

 

 

Depreciation

 

691

 

539

 

16,223

Amortization

 

10,574

 

15,639

 

9,538,281

Impairment on oil lease investments 

 

-

 

-

 

5,076,667

Stock issued for services 

 

1,675,180

 

544,600

 

36,472,866

Loss (gain) on settlement of debt 

 

2,371,700

 

1,477,000

 

8,612,888

Loss (gain) on acquisition write-off

 

-

 

-

 

36,500

Changes in operating assets and liabilities: 

 

 

 

 

 

 

Accounts receivable 

 

-

 

-

 

(2,087)

Prepaid expenses and deposits

 

14,882

 

-

 

(9,794)

Inventory 

 

-

 

-

 

(29,102)

Accounts payable 

 

58,327

 

(2,721)

 

1,587,864

Deferred license revenue

 

(73,334)

 

-

 

-

Accrued expenses 

 

390,318

 

(33,123)

 

11,263

Due to related parties 

 

-

 

79,000

 

66,500

Accrued interest payable to affiliate 

 

-

 

-

 

214,892

CASH FLOWS USED IN OPERATING ACTIVITIES 

 

 

 

 

 

 

FROM CONTINUING OPERATIONS 

 

(108,410)

 

(133,641)

 

(3,560,338)

CASH FLOWS PROVIDED BY OPERATING

 

 

 

 

 

 

ACTIVITIES FROM DISCONTINUED OPERATIONS

 

-

 

-

 

898,927

NET CASH USED IN OPERATING ACTIVITIES 

 

(108,410)

(133,641)

 

(2,661,411)

CASH FLOWS FROM INVESTING ACTIVITIES 

 

 

 

 

 

 

Purchase of oil & gas leases 

 

-

 

-

 

(30,000)

Purchase of property, plant & equipment 

 

-

 

-

 

(43,522)

CASH FLOWS USED IN INVESTING ACTIVITIES 

 

-

 

-

 

(73,522)

CASH FLOWS FROM FINANCING ACTIVITIES 

 

 

 

 

 

 

Proceeds from convertible note-related party 

 

-

 

-

 

951,342

Proceeds from advances from officer

 

-

 

-

 

94,307

Repayments on advances from officer

 

(1,807)

 

-

 

(73,807)

Proceeds from notes payable-stockholders

 

63,646

 

-

 

205,346

Repayments on notes payable-stockholders

 

-

 

-

 

(691)

Advances from related parties 

 

46,323

 

-

 

1,200,516

Proceeds from sale of common stock 

 

-

 

133,786

 

358,861

CASH FLOWS PROVIDED BY FINANCING ACTIVITIES 

 

108,162

 

133,786

 

2,735,875

NET INCREASE (DECREASE) IN CASH 

 

(248)

 

145

 

942

CASH, BEGINNING OF PERIOD 

 

1,190

 

243

 

-

CASH, END OF PERIOD 

 

942

 

388

 

942

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

 

 

Related party note payable 

 

-

 

-

 

250,000 

Net liabilities assumed with recapitalization 

 

-

 

275,000

 

200,000

Divestiture of subsidiary to related party 

 

-

 

-

 

544,340

Common stock issued for debt 

 

39,300

 

1,813,000

 

1,188,300

Common stock issued for acquiring 

 

 

 

 

 

 

  oil and gas leases 

 

-

 

-

 

7,906,200

Issuance of common stock for assets 

 

-

 

-

 

135,000

Issuance of preferred stock for services 

 

-

 

-

 

1,000

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these financial statements.

 

 

 

F-5

                 

              



CANNABIS SCIENCE, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2011


1.  SUMMARY OF SIGNIFICICANT ACCOUNTING POLICIES


A. Organization and General Description of Business


Cannabis Science, Inc.  (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc.  On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation.  On March 25, 2008 the Company changed its name to Gulf Onshore, Inc.  


On March 30, 2009, the Company acquired certain assets used to conduct a cannabis research and development business from Steven W. Kubby and Cannex Therapeutics, LLC, (“Cannex”). .  The asset purchase agreement included all of Cannex’ and Kubby’s intellectual property rights, formulas, patents, trademarks, client base, hardware and software, including the website www.phytiva.com.  


On April 7, 2009, the Company changed its name to Cannabis Science, Inc., reflecting its new business mission.  


The Company is in the business of developing pharmaceutical grade medical cannabis (marijuana) products.  We are working with scientific experts on phytocannabinoid science targeting critical illnesses; adhering to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.  In sum, the Company is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.   


Cannabis Science Inc. website is www.cannabisscience.com.

 

On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTCBB: CBIS.

On May 8, 2010, the Company entered into a share purchase agreement to acquire Rockbrook, Inc., a Colorado dispensary in exchange for 400,000 restricted common shares in the Company.  Due to a change in Colorado legislation preventing outside residents from owning a dispensary within the state, the Company and the sole Rockbrook shareholder agreed to and entered into a Mutual Termination Agreement on July 27, 2010 to retroactively cancel the acquisition.


On July 27, 2010, the Company signed a mutual termination agreement (“MTA”) to cancel the Share Purchase Agreement to acquire Rockbrook Inc. (“Rockbrook”).   Due to regulatory changes in the state of Colorado it was no longer permissible for the Company to own Rockbrook, a Colorado dispensary, and therefore the May 8, 2010 acquisition was retroactively cancelled along with the 400,000 restricted common shares issued on May 14, 2010 to the sole shareholder of Rockbrook.  The Company had not yet taken possession of Rockbrook shares or assets at the time of signing the MTA.

On June 8, 2011, a new and non-exclusive license agreement was signed with Rockbrook.  Under the terms of the new agreement, the Company will share revenues on a 50/50 basis with Rockbrook for any Company products sold through the Rockbrook dispensary.  In addition, the Company is released from prior agreements and the world-wide exclusivity clause in the original license agreement, which will permit the Company to pursue other product license and sales agreements.

 

F-6

                 

              


B.  Basis of Presentation


These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in US dollars.  The Company’s fiscal year end is December 31.


C.  Interim Financial Statement


These statements reflect all normal recurring adjustments, which, in the opinion of management, are necessary for the fair presentation of financial position, results of operations and cash flows for the periods presented.   The accompanying financial statements should be read in conjunction with Cannabis Science Inc’s financial statements for the years ended December 31, 2010 and 2009 filed in the Company’s Form 10-K dated April 15, 2011, which includes all disclosures required by accounting principles generally accepted in the United States of America, or GAAP. The results of operations for the periods ended June 30, 2011 and 2010 are not necessarily indicative of expected operating results for the full year.

 

D.  Use of Estimates


The preparation of these financial statements in conformity with US generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  The Company regularly evaluates estimates and assumptions related to stock-based compensation and deferred income tax valuations.  The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.  The actual results experienced by the Company may differ materially and adversely from the Company’s estimates.  To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.


E.  Basic and Diluted Net Income (Loss) Per Share


Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share.  Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity.  For the periods April 1, 2011 to June 30, 2011, January 1, 2011 to June 30, 2011, and from inception through June 30, 2011, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.

 

F.  Cash and Cash Equivalents


The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.


G. Fair Value Measurements


ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and requires certain disclosures about fair value measurements.  In general, fair values of financial instruments are based upon quoted market prices, where available.  If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters.  Valuation adjustments may be made to ensure that financial instruments are recorded at fair value.  These adjustments may include amounts to reflect counterparty credit quality and the customer’s creditworthiness, among other things, as well as unobservable parameters.  Any such valuation adjustments are applied consistently over time.  


H. Income Taxes


Under ASC 740, “Income Tax”, the Company is required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards.  Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.


Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards.  A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.


I. Stock-Based Compensation


Effective January 1, 2006, the Company adopted ASC 718-10, Compensation - Stock Compensation ("ASC 718-10"), using the modified-prospective method. Under ASC 718-10, share-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense, net of estimated pre-vesting forfeitures, ratably over the applicable period of the award.  


J.  Development Stage Enterprise


The Company is currently in the development stage as defined under the provisions of Accounting Codification Standard ("ASC") 915-10.  In October 2008, the Company divested itself of its operating company, Curado Energy Resources, Inc.  Beginning with the fiscal fourth quarter of 2008 the Company again became a development stage company.  The Company is working on developing its medical cannabis business, which will be comprised of cannabinoid medicines approved through the FDA along with non-psychotropic medicines for the naturopathy market.

 

 

F-7

                 

              



K. Recent Accounting Pronouncements


During the year ended December 31, 2010 and through August 12, 2011, there were several new accounting pronouncements issued by the FASB the most recent of which was Accounting Standards Update 2011-07.  Each of these pronouncements, as applicable, has been or will be adopted by the Company.  Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.


L. Reclassifications


For comparative purposes, certain prior period financial statements have been reclassified to conform with report classifications of the current year. [depreciation and amortization were separate where previously reported as a combined figure for comparative periods]


2.  GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern.  The Company reported an accumulated deficit of $66,754,373 and had a stockholder’s deficit of $1,797,024 at June 30, 2011.

 

In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital.  At June 30, 2011, the Company had minimal operations.  There can be no assurance that management will be successful in implementing its plans.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

We anticipate that we will have to raise additional capital to fund operations over the next 12 months.  To the extent that we are required to raise additional funds to acquire research and growing facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities.  There are no  commitments  or arrangements  for  other  offerings  in  place,  no  guaranties  that  any  such financings would be forthcoming,  or as to the terms of any such financings.  Any future financing may involve substantial dilution to existing investors.  We had been relying on our common stock to pay third parties for services which has resulted substantial dilution to existing investors.


3.  RELATED PARTY TRANSACTIONS


As of June 30, 2011, a total of $154,158 (December 31, 2010: $107,835) was due to a related parties.  The amounts due are non-interest bearing, unsecured and have no specified terms of repayment.  This related party also performs management services to the Company under a Management Consulting Agreement signed on July 1, 2010.



4.  NOTES PAYABLE


As of June 30, 2011, a total of $195,855 (December 31, 2010: $171,509) of notes payable are due to stockholders.  A total of $9 is due to a stockholder under a convertible note that is non-interest bearing and has no specified terms of repayment.  $195,846 is due to stockholders under promissory notes that are non-interested bearing and are due 12 months from the date of issue and loan origination beginning on July 30, 2011 through June 29, 2012.  One of the stockholders, to whom $184,200 in promissory notes are payable, also performs business and accounting services for the Company on a month-to-month basis.


5.  COMMON STOCK


During the three-months ended June 30, 2011, the Company issued the following common stock:


On May 16, 2011, the Company issued 5,000,000 common shares, with a fair market value of $0.05 per share, for settlement of $5,000 of shareholder debt assigned from the shareholder note payable originating on March 30, 2010 and April 12, 2010 and owing at December 31, 2010.


On June 1, 2011, the Company issued 5,000,000 common shares, with a fair market value of $0.04 per share, for settlement of $5,000 of shareholder debt assigned from the shareholder note payable originating on October 7, 2010 and owing at December 31, 2010. 


On June 7, 2011, the Company issued 1,250,000 common shares with a fair market value of $53,625 to several consultants for services rendered to the Company.


On June 13, 2011, the Company issued 3,800,000 common shares, with a fair market value of $0.04 per share, for settlement of $3,800 of shareholder debt assigned from the shareholder note payable originating on March 30, 2010 and April 12, 2010 and owing at December 31, 2010.


On June 15, 2011, the Company issued 1,000,000 common shares with a fair market value of $40,000 to a consultant for services rendered to the Company.


On June 24, 2011, the Company issued 3,800,000 common shares, with a fair market value of $0.04 per share, for settlement of $3,800 of shareholder debt assigned from the shareholder note payable originating on June 7, 2010 and owing at December 31, 2010.


On June 29, 2011, the Company issued 3,800,000 common shares, with a fair market value of $0.04 per share, for settlement of $3,800 of shareholder debt assigned from the shareholder note payable originating on December 16, 2010 and owing at December 31, 2010.




F-8

                 

              



6.  EQUIPMENT


Equipment

 $  1,267        

Computer

       223

 $  1,490


Computer and equipment are stated at cost.  Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized.  Depreciation is computed using the straight-line method over the estimated lives of the related assets, 2 years for computer and 5 years for equipment.



7. INTANGIBLE ASSETS


Intellectual assets, primarily intellectual property                 $ 126,000

Less accumulated amortization

       67,838

   $   58,162

       

   

Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (5 years for intellectual assets).                   


8.  COMMITMENTS


 

Payments due by period

 

Total

< 1 Year

1-3 Years

3-5Years

> 5 Years

Operating Lease

$237,711

$47,841

$101,651

$88,219

$0


On June 8, 2011, the Company signed a Consulting Agreement with a Consultant.  Under the Agreement, the Company shall issue 1,500,000 144-restricted common shares to the Consultant  upon successfully raising $1,000,000 at $0.10 per common share for the Company.


9.  SUBSEQUENT EVENTS


On July 26, 2011, the Company issued 1,400,000 common shares, with a fair market value of $0.04 per share, for settlement of $1,400 of shareholder debt assigned from the shareholder note payable originating on June 7, 2010 and owing at December 31, 2010.


On July 27, 2011, the Company issued 6,000,000 common shares, with a fair market value of $0.04 per share, for settlement of $6,000 of shareholder debt assigned from the shareholder note payable originating on July 9, 2010 and owing at December 31, 2010.


On July 28, 2011, the Company issued 3,000,000 common shares, with a fair market value of $0.04 per share, for settlement of $3,000 of shareholder debt assigned from the shareholder note payable originating on June 7, 2010 and owing at December 31, 2010.


On August 8, 2011, the Company issued 3,400,000 common shares, with a fair market value of $0.04 per share, for settlement of $3,400 of shareholder debt assigned from the shareholder note payable originating on December 16, 2010 and owing at December 31, 2010.

 


F-9

                 

              


PART I


This Interim Report on Form 10-Q contains forward-looking statements that have been made pursuant to the provisions of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from historical results or from those projected in the forward-looking statements.  Discussions containing forward-looking statements may be found in the material set forth under “Business,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in other sections of this Form 10-Q. Words such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable as of the date of this Report, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Interim Report on Form 10-Q.  We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations.


Readers should carefully review and consider the various disclosures made by us in this Report, set forth in detail in Part I, under the heading “Risk Factors,” as well as those additional risks described in other documents we file from time to time with the Securities and Exchange Commission, which attempt to advise interested parties of the risks, uncertainties, and other factors that affect our business.  We undertake no obligation to publicly release the results of any revisions to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.


ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


This section of this report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance.  Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events.  You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report.  These forward-looking states are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.


Overview of the Company’s Business


Cannabis Science, Inc. (formerly Gulf Onshore, Inc.)  (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc.  On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc., and commenced a business plan to develop Magkelate, a patented intravenous drug developed to re-establish normal electrolyte balance in ischemic tissue and certain other patents for medical instruments and medical instrument technology.  On January 14, 2000, the Company filed its Form 10SB12G.  In 2002, the Company ceased its medical technology business following the death of Magkelate’s inventor.  The Company conducted no substantial business until 2005.

  

4

                 

              

 

Liquidity


The Company has a working capital deficit of $1,863,342 as of June 30, 2011 compared to a working capital deficit of $1,404,039 for the year ended December 31, 2010.  There are insufficient liquid assets to meet current liabilities or sustain operations through 2011 and beyond and the Company must raise additional capital to cover the working capital deficit.  Management is working on plans to raise additional capital through private placements and lending facilities.


The Company has promissory note payment commitments of $195,855 due to stockholders over the next 12 months beginning on July 30, 2011 through June 30, 2012.


Contractual Obligations


 

Payments due by period

 

Total

< 1 Year

1-4 Years

3-5Years

> 5 Years

Operating Lease

$237,711

$47,841

$101,651

$88,219

$0


On June 8, 2011, the Company signed a Consulting Agreement with a Consultant.  Under the Agreement, the Company shall issue 1,500,000 144-restricted common shares to the Consultant upon successfully raising $1,000,000 at $0.10 per common share for the Company.


Capital Resources


The Company has capital resource requirements for laboratory and scientific equipment of approximately $325,000 over the next 12 months.  These capital disbursements are dependent on management’s successful raising of capital through private placements and lending facilities.


Results of Operations


The Company had license revenues of $62,044 and $73,334 for the three and six month periods ended June 30, 2011, respectively, compared to $0 for both comparative prior year periods.  These increases resulted from the Company’s license agreement with Rockbrook signed on August 18, 2010 and the associated recognition of license fees paid by Rockbrook to the Company for the distribution of its products.  


Net loss on settlement of liabilities decreased by $122,400 to $884,600 for the three months ended June 30, 2011 compared to $1,007,000 for the three months ended June 30, 2010.  This decrease was due to the Company settling less debt.  For the six months ended June 30, 2011 the net loss on settlement of liabilities increased by $894,700 to $2,371,700 compared to $1,477,000 for the comparable prior year period.  This increase was due to the Company settling debt at decreased settlement prices.


General and administrative expenses increased by $302,948 to $889,750 for the three months ended June 30, 2011 compared to $568,802 for the three months ended June 30, 2010.  General and administrative expenses increased by $1,512,632 to $2,186,359 for the six months ended June 30, 2011 compared to $673,727 for the three months ended June 30, 2010.  These increases are due to increased compensation from new management consulting agreements signed on July 1, 2010 and increased management and consulting expense from stock issued to consultants for services rendered.


The Company is in the development stage as defined in ASC 915.

 

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.


ITEM 4.  CONTROLS AND PROCEDURES


Our Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report, have concluded that, based on the evaluation of these controls and procedures, that our disclosure controls and procedures were not effective.


There were no changes in our internal controls or in other factors during the period covered by this report that have materially affected, or are likely to materially affect the Company’s internal controls over financial reporting.

 

 

5

                 

              



PART II OTHER INFORMATION



ITEM 1.  LEGAL PROCEEDINGS

None.  

 

ITEM 1A.  RISK FACTORS

Not applicable.

 

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS


During the three months ended June 30, 2011, we have issued securities using exemptions available under the Securities Act of 1933:


As set out below, we have issued securities in exchange for services, properties and for debt:


On May 16, 2011, the Company issued 5,000,000 common shares, with a fair market value of $0.05 per share, for settlement of $5,000 of shareholder debt assigned from the shareholder note payable originating on March 30, 2010 and April 12, 2010 and owing at December 31, 2010.


On June 1, 2011, the Company issued 5,000,000 common shares, with a fair market value of $0.04 per share, for settlement of $5,000 of shareholder debt assigned from the shareholder note payable originating on October 7, 2010 and owing at December 31, 2010. 


On June 7, 2011, the Company issued 1,250,000 common shares with a fair market value of $53,625 to several consultants for services rendered to the Company.


On June 13, 2011, the Company issued 3,800,000 common shares, with a fair market value of $0.04 per share, for settlement of $3,800 of shareholder debt assigned from the shareholder note payable originating on March 30, 2010 and April 12, 2010 and owing at December 31, 2010.


On June 15, 2011, the Company issued 1,000,000 common shares with a fair market value of $40,000 to a consultant for services rendered to the Company.


On June 24, 2011, the Company issued 3,800,000 common shares, with a fair market value of $0.04 per share, for settlement of $3,800 of shareholder debt assigned from the shareholder note payable originating on June 7, 2010 and owing at December 31, 2010.


On June 29, 2011, the Company issued 3,800,000 common shares, with a fair market value of $0.04 per share, for settlement of $3,800 of shareholder debt assigned from the shareholder note payable originating on December 16, 2010 and owing at December 31, 2010. 

 


6

                 

              



ITEM 3.  DEFAULTS UPON SENIOR SECURITIES


None.


ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


None.


ITEM 5.  OTHER INFORMATION


None.


ITEM 6. EXHIBITS

31.1         Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

31.2         Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.1         Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.2         Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

101.INS   XBRL Instance Document

101.SCH  XBRL Taxonomy Extension Schema

101.CAL  XBRL Taxonomy Extension Calculation Linkbase

101.LAB  XBRL Taxonomy Extension Label Linkbase

101.PRE  XBRL Taxonomy Extension Presentation Linkbase

101.DEF  XBRL Taxonomy Extension Definition Linkbase

7

                 

              

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.



  

CANNABIS SCIENCE INC.

 

 

(REGISTRANT)

  

 

Date:  September 16, 2011

/s/ Dr. Robert Melamede

 

 

Dr. Robert Melamede

  

 

President, Chief Executive Officer and Director

 

 

(Authorized Officer for Registrant)



 

 

Date:  September 16, 2011

/s/ Richard Cowan

 

 

Richard Cowan

  

 

Chief Financial Officer and Director

 

 

 

 

 

 



8